Navigation Links
15-Minute Data From Phase 3 Study of Avanafil Featured as a Late Breaking Abstract at SMSNA Annual Meeting
Date:11/14/2011

MOUNTAIN VIEW, Calif., Nov. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that new analyses from TA-314, a phase 3 long-term safety and efficacy study of the investigational drug avanafil for the treatment of erectile dysfunction (ED), was presented over the weekend at the 2011 Sexual Medicine Society of North America (SMSNA) Meeting in Las Vegas, NV.  Andrew R. McCullough, MD, Professor of Surgery/Urology at Albany Medical College, presented the analysis of results from the study that showed that avanafil was effective in as early as 15 minutes after dosing when analyzed both by subject and attempt.  Of the subjects attempting intercourse </=15 minutes of dosing, 83% had successful intercourse.  Additionally, eighty percent (80%) of all study-wide sexual attempts made within 15 minutes of dosing were successful.

The study entitled, "An Open-label, Long-term Evaluation of the Safety and Efficacy of Avanafil in Men with Erectile Dysfunction" was presented during the Late Breaking Trials Session on November 12, 2011.  Dr. McCullough concluded that based on the results of the study, this onset of action suggests that avanafil, if approved, is potentially well-suited for on-demand treatment in men with mild to severe ED.

About AvanafilAvanafil is an investigational oral drug being developed for the treatment of erectile dysfunction.  Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma Corporation.  VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian Pacific Rim countries.

About VIVUSVIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health.  The company's lead investigational product in c
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
3. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
4. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
5. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
6. PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet
7. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
8. Michigan Innovation Equipment Depot Launches Next Phase of Distribution
9. Phase 1b/2a Program Commences for RVX-208
10. Chiltern Early Phase: Fully Integrated and Business Ready
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... Massachusetts, USA (PRWEB) November 26, 2014 ... more accuracy, additive systems to enable 3D manufacture at ... analyzing road conditions are among finalists in nine categories ... . The awards are sponsored by SPIE, the ... Photonics Media . , Winners will be announced by ...
(Date:11/26/2014)... Dallas, Texas (PRWEB) November 26, 2014 ... Bifluoride Industryā€¯ is a professional and in-depth research ... Ammonium Bifluoride information, like its definition, classification, application, ... overview. This report covers the international market analysis, ... (such as the US, Europe, Asia, China, Japan ...
(Date:11/26/2014)... , Nov. 26, 2014 The announced ... indicate the company is looking to expand in non-healthcare ... sales.  The healthcare market research firm says that  Siemens ... Kalorama Information,s biennial survey of the IVD market , ... any change in its composition would likely affect IVD ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 On January, ... the Baltimore and Washington D.C. science community to the ... The event, sponsored by the Protein Society, will take ... University Center, Room 312. Through discussion, presentations and ... structural importance of proteins, their role in the industry ...
Breaking Biology Technology:Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2
... ... President, Marketing and Sales, and James Carr Promoted To ... Capacity in China -, - Details to be Presented at Investor Briefing Today at 12 p.m. Eastern ... Time -, SOUTH SAN FRANCISCO, Calif., ...
... Ill. A hybrid device combining force and fluorescence ... made possible the accurate detection of nanometer-scale motion of ... resonance energy transfer and an optical trap, we now ... of a biomolecule at an extremely low applied force, ...
... Oct. 11 Timely Data Resources, Inc.,has recently released ... and Therapy,Review (DTR) reports. Reports are available through subscription ... be purchased,individually at marketresearch.com. These reports offer a quick ... Each overview is,generally 10 to 15 pages in length, ...
Cached Biology Technology:Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 2Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 3Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 4Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 5Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 6Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM) 7New force-fluorescence device measures motion previously undetectable 2New force-fluorescence device measures motion previously undetectable 3
(Date:11/3/2014)... and preterm birth are linked to increased risk for ... the American College of Rheumatology (ACR) journal, Arthritis ... and pre-term babies were not at greater risk of ... According to the ACR, 27 million Americans over the ... of OA range from mild to severe and include ...
(Date:11/2/2014)... NEW ORLEANS, LA (2 November 2014)—In support of a ... the Bill & Melinda Gates Foundation today announced an ... PATH Malaria Vaccine Initiative (MVI) in building new vaccines ... and help realize the "accelerating to zero" agenda. Such ... providing what could be called an "immunological bed net." ...
(Date:11/2/2014)... and bump into a biologist . . . , While ... sketch, researchers have taken this premise and applied it to ... in the rising oceans of genomic data. , In this ... studies are publishing at a dizzying rate. The challenge is ... the noise (and there is no shortage of noise). , ...
Breaking Biology News(10 mins):Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4Mutant models 2Mutant models 3Mutant models 4
... the molecular details that show how a viral protein ... them to continuously grow, thereby predisposing people to certain ... of the most common human viruses in the world ... Burkitt's lymphoma as well as the epithelial cell cancer, ...
... aimed at directly controlling the expression of genes by turning ... to drugs for the treatment or cure of many diseases, ... disease starts at the level of malfunctioning gene expression, or ... of pharmacology and biochemistry. "This is an approach that could ...
... cells make their vital connections, embryonic cells move to ... in to destroy pathogenic organisms, and cancer cells metastasize, ... migrations didn't know how cells determined where to go. ... a fragment of a protein that senses chemicals that ...
Cached Biology News:U of T researchers map role of Epstein-Barr virus in cancer 2Gene silencing technique offers new strategy for treating, curing disease 2New understanding of cell movement may yield ways to brake cancer's spread 2
ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
... is a thermostable DNA polymerase derived ... at temperatures above 70°C, it was ... PCR and remains the predominant enzyme ... an intrinsic 5'?3' structure-dependent exonuclease activity, ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
... number is a new ... easily match Cornings product ... availability yet, please order ... number (Z71,448-8) or contact ...
Biology Products: